1. Next Biomedical IR: What was discussed?

Next Biomedical presented its key management status and business progress, followed by a Q&A session with investors on September 8, 2025. The core focus of this IR was Nexpowder™’s global market expansion strategy, Nexsphere™-F’s US FDA approval and market entry roadmap, and plans for profitability improvement.

2. Key Analysis: Why is it important?

  • Continued Nexpowder™ Growth: Sales reached 6.544 billion KRW in the first half of 2025, a 20.98% increase year-over-year, with plans to accelerate global expansion through US FDA approval and the Medtronic partnership.
  • Nexsphere™-F FDA Approval Expectations: Expectations for US market entry are rising with the US FDA Breakthrough Device Designation and Medicare approval.
  • Profitability Improvement Challenges: Improving the deficit structure due to high R&D and SG&A expenses is urgent.

3. Future Outlook and Investment Strategy: What should investors do?

Next Biomedical possesses an innovative product portfolio, but securing profitability is a critical challenge. Investors should carefully review the feasibility of the profitability improvement strategies presented at the IR, the speed of Nexpowder™’s global market expansion, and the roadmap for Nexsphere™-F’s FDA approval and market entry.

4. Action Plan for Investors

  • Analyze IR materials and management responses
  • Refer to securities firm reports (to be published)
  • Evaluate company value and make investment decisions